PT538 – Rumination, the Default Mode Network, and How Neuroplasticity Changes Over Time, with Dr. Jerry Rosenbaum & Sharmin Ghaznavi, MD, Ph.D.
Psychedelics Today
Psychedelics Today, LLC
4.6 • 598 Ratings
🗓️ 13 August 2024
⏱️ 63 minutes
🧾️ Download transcript
Summary
In this episode, Chris Koddermann interviews two members of the Center for the Neuroscience of Psychedelics at Mass General Hospital: founding director, author, and co-founder of three drug development companies, Dr. Jerry Rosenbaum; and psychiatrist and associate director and director of cognitive neuroscience, Sharmin Ghaznavi, MD, Ph.D.
Rosenbaum and Ghaznavi bonded over an interest in rumination, and wondered: How could the plasticity-inducing effects of psychedelics change these negative loops people find themselves in? How important is the ability to break out of those loops – and learn new patterns – when our concept of self is so central to who we are? Ghaznavi is studying the effects of psilocybin on rumination and scanning patients at multiple times throughout the process to track data we still don't really have: how psychedelic-induced neuroplasticity changes over time, and why.
They discuss:
- How much of a role the default mode network takes in the therapeutic benefits of psychedelics: Is it overblown?
- Hyperscanning, which involves scanning two individuals at the same time, looking for potential concordance in signal and/or an increased alliance between the therapist and patient
- The Schultes Legacy Project and the work of Stephen Haggarty to explore the potential of largely unstudied psychoactive plants
- Critiques of the recent ruling on Lykos and MDMA-assisted therapy and the clash between the FDA and the advisory committee: Were they really on the same page?
- The false dichotomy of neuroscience vs. patient experience: Does the subjective experience actually increase plasticity and other measurable benefits?
and more!
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hello and welcome back to Psychedelics Today. |
| 0:14.5 | I'm Chris Coterman, and today I have the pleasure of speaking with Dr. Jerry Rosenbaum and Dr. |
| 0:19.7 | Sharman-Gaznavi of the Center for the Neuroscience |
| 0:22.6 | of Psychedelics at Massachusetts General Hospital, where they serve respectively as founding director |
| 0:27.7 | and associate director. Dr. Rosenbaum has a long and distinguished career and is recognized as one of |
| 0:33.2 | the world's foremost authorities on mood and anxiety disorders. In addition to his role as the |
| 0:38.7 | Stanley called professor of psychiatry at Harvard Medical School, Dr. Rosenbaum served as the |
| 0:43.6 | chief of psychiatry at Massachusetts General Hospital for 20 years until transitioning into |
| 0:48.8 | the role of psychiatrist and chief emeritus in 2019. Under his stewardship, MGH's psychiatry department was |
| 0:56.4 | ranked by U.S. News and World Report as number one in the United States in 2019 and for 20 of the 24 |
| 1:03.2 | prior years. Dr. Rosenbaum is also currently serving as the Director of MGH's Center for |
| 1:10.3 | Anxiety and Traumatic Stress |
| 1:11.7 | Disorders. A recipient of numerous awards and accolades and author of over 400 articles and 12 books, |
| 1:18.3 | Dr. Rosenbaum is also the co-founder of three drug development companies, namely Sensorium |
| 1:23.6 | therapeutics, and Theos Labs and Cy Therapeutics. Dr. Sherman Gisnavi, in addition to being |
| 1:29.6 | the Associate Director of the Center for the Neuroscience of Psychedelics, is also the center's |
| 1:33.9 | director of cognitive neuroscience. Dr. Gazznavi also serves as a psychiatrist at the |
| 1:39.1 | Dowton Family Center for Bipolar Treatment, Innovation, and as an instructor at Harvard Medical |
| 1:43.6 | School. |
| 1:49.2 | Her research interests include the neurocorrelates of rumination, self-reported processing, |
| 1:51.9 | and other cognitive processes underlying mental illness. |
| 1:57.3 | Dr. Gazzonavi received her undergraduate degrees in biology and brain and cognitive sciences and philosophy from the Massachusetts Institute of Technology. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Psychedelics Today, LLC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Psychedelics Today, LLC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.